Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
AMCP Annual Meeting
Is Pemetrexed/Platinum Therapy Cost-Effective in NSCLC?
By
Audrey Andrews
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—In what appears to be the first study to use real-world, non–clinical trial data to evaluate the cost-effectiveness of pemetrexed/platinum (Pem/P) therapy used first line in patients with advanced non–smallcell lung cancer (NSCLC), this combination trended toward being more effective and less costly than carboplatin/ paclitaxel plus bevacizumab (C/Pa+B), reported Manan Shah, PharmD, PhD, with Xcenda, Palm Harbor, FL, and colleagues at the 2012 Academy of Managed Care Pharmacy annual meeting.
Read Article
In Colorectal Cancer, Treatment Efficacy Is High Among the Elderly
By
Caroline Helwick
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—The vast majority of published evidence indicates that the relative treatment effect of chemotherapy for stage III colon cancer is as good for elderly patients as it is for younger ones, according to a systematic literature review by Anna Hung, a student in the program, and C. Daniel Mullins, PhD, Professor, Pharmacoeconomics, Pharmaceutical Health Services Research Department, Associate Director, Center on Drugs and Public Policy.
Read Article
Does CMS’s Coverage Decision for Sipuleucel-T Herald More Restrictive Policy?
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—In its national coverage decision (NCD) for sipuleucel-T in the treatment of advanced prostate cancer, the Centers for Medicare & Medicaid Services (CMS) left the coverage decision for any off-label use of medications to the discretion of the local Medicare contractors, citing an absence of data on which to make a coverage decision.
Read Article
Vemurafenib Does Not Impact Health Plan Budget
By
Caroline Helwick
AMCP Annual Meeting
July 2012, Vol 3, No 5
Although the upfront cost of vemurafenib is high, its use to treat patients with metastatic melanoma actually results in a costsavings per health plan member per month (PMPM), according to an analysis presented at the 2012 Academy of Managed Care Pharmacy annual meeting.
Read Article
Oncology Genetic Testing: Pharmacists’ Knowledge Gap
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—Knowledge of pharmacogenomics—the genomic factors contributing to individual variability in response to drug therapy (or personalized medicine)—enhances the ability to diagnose, prevent, and treat disease, especially a variety of cancers.
Read Article
An Early Look at New Drugs on the Horizon
AMCP Annual Meeting
June 2010, Vol 1, No 2
Washington, DC—A first look at new cancer therapies was the focus of the 6th annual New Drugs on the Horizon symposium held as a special session at the American Association for Cancer Research (AACR) annual meeting.
Read Article
Pemetrexed as Maintenance Therapy Likely to Have ‘Minimal Impact’ on Health Plan Budget
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—In the first study to estimate the budgetary impact of accepting pemetrexed as maintenance therapy for non–small-cell lung cancer (NSCLC), researchers found that adopting the drug did not significantly affect a health plan’s budget.
Read Article
Researchers Analyze Relationship Between Pharmacogenomics and Appropriate Oncology Care
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—Pharmacogenomic (PGx) testing seeks to optimize treatment by ensuring patients receive the bestsuited drug based on interindividual genetic variation. Currently, no published data exist on how this may influence the appropriateness of oncology treatment within a utilization management program. Seeking to remedy this, researchers from CVS Caremark (Northbrook, IL) analyzed data from their own utilization management program, within which PGx testing requirements are implemented for certain oncology therapies and specific indications.
Read Article
Survey Provides a Window Into Payers’ Decision-Making Process
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—Payers believe that prescribing information, national guidelines, and prospective controlled randomized trials (PCRTs) are the most useful sources of information about oncology drugs, according to researchers from Genentech, Inc (South San Francisco).
Read Article
Patients More Likely to Abandon Drug Therapy When Paying More Out of Pocket
AMCP Annual Meeting
June 2010, Vol 1, No 2
San Diego—For health plans attempting to cut costs, instituting higher out-of-pocket (OOP) payments for patients taking oral oncology drugs may not be a prudent solution, according to research presented at the AMCP’s annual meeting.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma